Intersect ENT (NASDAQ:XENT) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Intersect ENT (NASDAQ:XENT) from a sell rating to a hold rating in a report published on Saturday morning, BidAskClub reports.

Other equities analysts have also recently issued reports about the company. ValuEngine raised Intersect ENT from a hold rating to a buy rating in a report on Thursday, August 1st. Piper Jaffray Companies cut Intersect ENT from an overweight rating to a neutral rating and lowered their price target for the company from $30.00 to $17.00 in a report on Friday, August 2nd. Northland Securities raised Intersect ENT from an under perform rating to a market perform rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Berenberg Bank cut Intersect ENT from a buy rating to a hold rating and lowered their price target for the company from $35.00 to $27.00 in a report on Friday, June 21st. Finally, Guggenheim cut Intersect ENT from a buy rating to a neutral rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $27.11.

NASDAQ XENT opened at $18.33 on Friday. The business’s fifty day moving average price is $16.85 and its 200-day moving average price is $24.49. The stock has a market capitalization of $576.58 million, a price-to-earnings ratio of -24.12 and a beta of 0.73. Intersect ENT has a 1-year low of $15.01 and a 1-year high of $35.87.



Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The firm had revenue of $26.66 million for the quarter, compared to the consensus estimate of $27.13 million. Intersect ENT had a negative net margin of 31.43% and a negative return on equity of 29.16%. Intersect ENT’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.14) earnings per share. As a group, analysts expect that Intersect ENT will post -1.44 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in XENT. Point72 Asset Management L.P. raised its holdings in Intersect ENT by 18,587.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,459,842 shares of the medical equipment provider’s stock worth $55,986,000 after purchasing an additional 2,446,679 shares during the period. FMR LLC raised its holdings in Intersect ENT by 1,863.8% in the 1st quarter. FMR LLC now owns 632,451 shares of the medical equipment provider’s stock worth $20,334,000 after purchasing an additional 600,246 shares during the period. Nuveen Asset Management LLC bought a new position in Intersect ENT in the 2nd quarter worth $12,782,000. Westfield Capital Management Co. LP raised its holdings in Intersect ENT by 86.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,214,025 shares of the medical equipment provider’s stock worth $27,631,000 after purchasing an additional 561,244 shares during the period. Finally, Invesco Ltd. raised its holdings in Intersect ENT by 24.5% in the 2nd quarter. Invesco Ltd. now owns 2,187,559 shares of the medical equipment provider’s stock worth $49,789,000 after purchasing an additional 430,279 shares during the period. 96.22% of the stock is currently owned by institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.